Researchers Examine Combination Chemotherapy in Patients With Advanced Prostate Cancer

Researchers Examine Combination Chemotherapy in Patients With Advanced Prostate Cancer
Currently, patients with metastatic castration-resistant prostate cancer (mCRPC) have been treated with cytotoxic chemotherapy with the sequential use of single agent taxanes such as docetaxel and cabazitaxel, used as a “first-line” and “second-line” treatments, respectively. During the American Society of Clinical Oncology meeting a team of researchers at The University of Texas MD Anderson Cancer Center presented the results

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *